Shareholder Alert: Ademi LLP investigates whether Taro Pharmaceutical Industries Limited has obtained a Fair Price for its Public Shareholders in its transaction with its majority shareholder, Sun Pharmaceutical Industries Limited.
Provided By PR Newswire
Last update: May 20, 2024
MILWAUKEE, May 20, 2024 /PRNewswire/ -- Ademi LLP is investigating Taro (NYSE: TARO) for possible breaches of fiduciary duty and other violations of law in its transaction with its majority shareholder Sun.
Read more at prnewswire.com
